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Abstract
Shortly after discovery of ET-1 in 1988, the entire en-
dothelin system was characterized. The endothelin sys-
tem consists of the three peptides ET-1, ET-2 and
ET-3, their G-protein-coupled receptors endothelin
receptor A and B (ETRA and ETRB) and the two en-
dothelin-converting enzymes (ECE-1 and ECE-2).
Genetically modified animal models are an important
tool in biomedical research. Here we describe the key
findings obtained from genetically modified animal
models either over-expressing compounds of the ET
system or lacking these compounds (knockout mice).
Results from the different transgenic and knockout
models disclose that the ET system plays a major role
in embryonic development. Two ET system-depen-
dent neural crest-driven developmental pathways be-
come obvious: one of them being an ET-1/ETAR
axis, responsible for cardio-renal function and deve-
lopment as well as cranial development; the other
seems to be an ET-3/ETBR mediated signalling path-
way. Mutations within this axis are associated with dis-
ruptions in epidermal melanocytes and enteric neu-
rons. These findings led to the discovery of similar
findings in humans with Hirschsprung disease. In
adult life the ET system is most important in the car-
diovascular system and plays a role in fibrotic remo-
delling of the heart, lung and kidney as well as in the
regulation of water and salt excretion.
INTRODUCTION
Genetically modified animal models are an important
part of medical research. By inducing conditions simi-
lar to human diseases in animals, pathophysiologic hy-
potheses and therapeutic strategies can be tested and
evaluated.
The endothelin (ET) system plays a complex role in
physiologic and pathophysiologic functions of the
body. In order to analyse the role of single compo-
nents of the endothelin system in specific organs and
tissues several transgenic and knockout (KO) animal
models have been developed.
The ET system consists of the three peptides ET-1,
ET-2 and ET-3, their G-protein-coupled receptors en-
dothelin receptor A and B (ETRA and ETRB) and the
two endothelin-converting enzymes (ECE-1 and
ECE-2) which convert the precursor big-ETs to the
biologically active forms. The ET system is expressed
in various tissues and cells. Its different components
are often counteracting in an autocrine and paracrine
way.
Because of its strong vasoconstrictive effect the ET
system plays a role in the development of hyperten-
sion and atherosclerosis. It is also involved in cardiac
diseases because of effects on inotropy and chrono-
tropy. ET has also been shown to be involved in states
of portal hypertension and acute and chronic renal
failure [1].
In the following, this article outlines the genetically
modified animal models, which have been established
in order to obtain a better understanding of the ET
system.
THE TRANSGENIC ANIMAL MODELS
A model in which the human ET-1 gene under the
control of its natural promoter was transferred into
the germline of mice was established independently by
two research groups [2, 3]. Both groups observed si-
milar results: the overexpression of the ET-1 gene cre-
ates a phenotype with characteristic, age-dependent
pathologic alterations of the kidney whilst blood pres-
sure remains normal. The most evident effects of the
elevated plasma and tissue concentrations of ET-1 are
the development of renal interstitial fibrosis, renal
cysts and glomerulosclerosis, leading to a progressive
decrease in glomerular filtration rate in aged mice. In
these transgenic models the profibrotic effect of ET-1
is most ostentatious whereas hypertension can only be
induced by salt-loading. This was unexpected since
previous studies showed ET-1 to be an potent vaso-
constrictor when administered intravenously [4-7].
A bolus injection of the nitric oxide synthesis in-
hibitor L-NAME induces an exaggerated hypertensive
response in ET-1 transgenic mice as well as in ET-2
transgenic rats [8, 9]. This suggests that the nitric
oxide system as a vasodilator system is involved.
In an animal model of crossbreds of ET-1 trans-
genic mice (ET+/+) and mice in which the gene for
the endothelial nitric oxide synthase (eNOS) was
knocked out [10] this assumption was supported.
Compared to the normotensive wild type and ET+/+,
the crossbred ET+/+ eNOS KO have a significantly
elevated blood pressure. This is also seen in ET+/+
inducible NOS KO crossbreds [11] which corrobo-
rates the hypothesis that the NO system counterregu-
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model leading to a normotensive phenotype.
The ET-1 transgenic model also brought out some
interesting findings about the role of endothelin in the
etiology of pulmonary diseases. The development of
pulmonary fibrosis and chronic lymphocytic inflam-
mation in the absence of pulmonary hypertension was
observed in the transgenic animals [12], suggesting
ET-1 to be involved in the pathogenesis of lung fibro-
sis and bronchiolitis.
Endothelium-restricted overexpression of human
ET-1 does not result in elevated blood pressure, how-
ever altered vascular structure and function in resis-
tance vessels can be observed. This is a sign of blood
pressure independent effects of endothelium-genera-
ted ET-1 on vasculature [13].
Conditional cardiac overexpression of endothelin-1
induces inflammation and dilated cardiomyopathy in
mice indicating that ET-1 acts as a proinflammatory
molecule in the heart [14].
In rats overexpressing the human ET-2 gene under
control of its natural promoter a blood pressure-inde-
pendent fibrotic remodelling of the kidney is seen but
is mainly restricted to the glomeruli. This is most
probably due to the preferential expression of the
transgene within the glomeruli in ET-2 transgenic ani-
mals [15], whereas the transgene is ubiquitously ex-
pressed within the entire kidney of ET-1 transgenic
mice [2].
ET-3 plays an important role in the development of
epidermal melanocytes [16]. A tetracyclin-responsive
melanocyte-specific lineage transgenic system was cre-
ated and used to conditionally regulate the overexpres-
sion of ET-3 in different stages of melanocyte deve-
lopment. Investigations showed that ET-3 interacts
with precursors and differentiated melanocytes [17].
The activation of the transgene in mice leads to a hy-
perpigmented phenotype both in embryonic develop-
ment and in mature mice.
THE KNOCKOUT ANIMAL MODELS
Homozygous ET-1 KO mice die within 15-30 minutes
after birth due to craniofacial abnormalities resulting
in an inability to breath normally [18]. Furthermore
they display malformations of cardiovascular system
[19], thymus and thyroid [20]. These affected tissues
and organs are predominantly formed by cranial neur-
al crest-derived ectomesenchymal cells. No abnormali-
ties in other organs such as the lung, kidney and cen-
tral nervous system can be observed.
Similar craniofacial and cardiovascular malforma-
tions are seen in mice with disruption of the ETAR
gene. The important role of ET-1 in skeletal develop-
ment during intrauterine life was recently confirmed
by using prepro-ET-1-lacZ-transgenic mice [21].
The examination of expression patterns of ETARs
and ET-1 suggests that ET-1/ETAR interaction is es-
sential in cranial bone and connective tissue formation
as well as in the development of the heart and its out-
flow tract [22].
Heterozygous ET-1 KO mice which have lower
serum levels of ET-1 than wild type mice paradoxical-
ly develop elevated blood pressure [18]. Enhanced
basal and hypercapnia-induced renal sympathetic
nerve activity in the heterozygous ET-1 KO mice
seem to be involved in elevation of blood pressure
[23, 24]. Some other causes that might contribute to
blood pressure elevation in heterozygous ET-1 KO
mice have been excluded, such as salt sensitivity or
respiratory abnormalities [25, 26].
Collecting duct (CD)-specific ET-1 KO mice do
not have gross morphologic abnormalities. Plasma
ET-1 levels are not affected, however urinary excretion
of ET-1 is reduced. CD ET-1 KO mice are hyperten-
sive but show no differences in body weight, urine vo-
lume, creatinine clearance, sodium and potassium ex-
cretion, urine and plasma osmolality, plasma aldos-
teron concentration and renin activity. CD ET-1 KO
mice are salt-sensitive and exhibit reduced sodium ex-
cretion during the first three days of high salt diet.
Amiloride and furosemide are able to prevent sodium
retention and exacerbation of hypertension. However,
they do not reduce blood pressure in CD ET-1 KO
mice on a normal sodium diet [27].
Plasma vasopressin (AVP) concentrations are sub-
stantially reduced in CD ET-1 KO mice, despite all
other aspects of water metabolism being similar. The
response to continuous infusion of 1-deamin-8-D-
arginine vasopressin is stronger in CD ET-1 KO mice.
There seems to be an increased renal sensitivity to the
effects of AVP suggesting that ET-1 acts as a physio-
logical autocrine regulator of AVP action in the col-
lecting duct [28].
Thus, CD-derived ET-1 seems to be an important
physiological regulator of renal salt and water handling
and systemic blood pressure.
CD-specific KO of the ETAR has no effect on
blood pressure or urinary sodium excretion in mice,
independently of salt intake. Those mice have in-
creased plasma AVP levels but do not show diffe-
rences of renal water excretion under baseline condi-
tions. However they have a more rapid decrease in
urine osmolality following an acute water loading.
During exogenous AVP infusion CD ETAR KO mice
increase urine osmolality similar to WT mice but have
a more rapid subsequent fall in urine osmolality during
sustained AVP administration. The lower AVP respon-
siveness in CD ETAR KO mice is contradictory to the
results seen in CD ET-1 KO mice. These animals have
elevated AVP sensitivity, and impaired ability to ex-
crete an acute water load. This implies that ET-1 must
exert its influence on vasopressin through CD ETBR
and/or through paracrine effects [29].
At 6 month of age mice with disruption of the ET-
1 gene in cardiomyocytes (CM ET-1 KO) have a sig-
nificantly lower fractional shortening and develop a di-
lated left ventricle (LV). During the next month the
left ventricle systolic function of CM ET-1 KO mice
declines and ultimately, they die at much younger ages
(median life expectancy of CM ET-1 KO: 11 months,
WT: 2 years). Histological characterization of the CM
ET-1 KO hearts reveal dilated heart chambers with
heterogeneity of myocyte size, increased fibrosis and
raised apoptosis.
At the age of 2 months, aortic banding leads to di-
lated cardiomyopathy in CM ET-1 KO mice but to LV
hypertrophy in WT mice [30].
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that increased apoptosis in CM ET-1 KO is mediated
by enhanced activity of tumor necrosis factor (TNF).
CM ET-1 KO hearts also have diminished NF-κB ac-
tivity, amounting to diminution of downstream in-
hibitors of TNF signaling [30].
CM ET-1 KO mice are resistant to the hypertrophic
stress of treatment with thyroid hormone. While mice
with intact ET-1 gene develop a pronounced LV hy-
pertrophy, CM ET-1 KO mice show only a marginal
increase in LV mass.
These findings indicate that the interaction of local-
ly produced ET-1 with thyroid hormone, is essential in
the development of thyroid hormone induced my-
ocardial hypertrophy [31].
There are no ET-2 knockout models described in
the published literature.
ET-3 KO mice exhibit aganglionic megacolon and
pigmentary disorders of the skin and choroidal layer
of the retina. These findings indicate that ET-3 is es-
sential in the development of two neural crest-derived
cell lineages, epidermal and choroidal melanozytes and
enteric ganglion neurons [16, 30, 32].
Blood pressure and heart rate of infant ET-3 KO
mice are not different from those in age matched WT
mice. These results suggest that ET-3 is not involved
in cardiovascular regulation at least in early life before
they die of complications of the megacolon [33].
Phenotypes of animals with natural mutations or
with a targeted disruption of the ETBR gene are simi-
lar to that of ET-3 KO animals [16, 34]. This under-
lines the importance of ET-3/ETBR-mediated signa-
ling in the development of melanocytes and enteric
neurons.
A naturally occurring rodent model of the de-
scribed phenotype is the spotting lethal (sl/sl) rat
which carries a deletion of the ETBR gene.
To establish a viable animal model it was necessary
to support a normal enteric nervous system develop-
ment. ETBR deficient sl/sl rats were rescued by
breeding them with rats harboring a dopamine-beta-
hydroxylase (DBH)-ETBR transgene. This transgene
leads to the development of a normal enteric nervous
system. The resulting transgenic rats (DBH-ETBR;
ETBRsl/sl) are healthy but present with total absence
of ETBR in all non-adrenergic tissues including the
kidneys [35]. Those ETBR-deficient rats are nor-
motensive on a sodium-deficient diet, mildly hyperten-
sive on a standard diet and exhibit severe hypertension
on a high-sodium diet [36].
Their endothelial function is impaired but it was
shown that it is independent of the salt-enriched diet
and therefore not responsible for the hypertension
[37].
In young sl/sl rats fractional sodium excretion is
markedly reduced. When treated with the specific epi-
thelial sodium channel blocker amiloride the animals
show increased excretion of sodium [38]. This seems
to be due to a lack of the inhibitory property of the
ETBR on the epithelial sodium channel activity. This
data indicates that a reduced renal ETBR activity
might contribute to a salt-sensitive hypertension.
The effect of the ETBR on the progression of dia-
betic nephropathy was analyzed by rendering the
transgenic animals diabetic with streptozotocin. These
animals develop severe hypertension and show an en-
hanced functional renal impairment compared to dia-
betic WT animals. Further analyses suggested the ele-
vated plasma levels of ET-1 to be responsible for the
hypertension and not the renin-angiotensin system or
the NO system [39].
In a model of endothelial cell-specific ETBR KO,
the animals showed endothelial dysfunction but no hy-
pertension in response to a high salt diet [40]. This
points out that the salt-induced hypertension seen in
the model of rescued ETBR-deficient rats is not medi-
ated by endothelial cells.
A CD-specific ETBR KO causes salt sensitive hy-
pertension and sodium retention [41]. Taken together
with the results from the CD-specific ET-1 KO, these
findings point out an ET-1/ETBR axis which has in-
fluence on systemic blood pressure at least partially
mediated through autocrine inhibition of CD sodium
reabsorption. Yet it is not only the renal ETBR which
is crucial for the hypertension since ETBR deficient
mice with transplanted normal kidneys are hyperten-
sive as well [42].
The highly specific ET converting-enzymes (ECEs)
are membrane-bound metalloproteases which catalyse
the cleavage of a Trp21 bond in the precursor big-en-
dothelins resulting in active endothelins. Two isoen-
zymes ECE-1 and ECE-2 have been identified [43, 44]
and their role in the ET system was investigated by
creating KO models.
Most of the ECE-1 KO animals die in utero be-
cause of an embryonic lethal phenotype of cardiac ab-
normalities. Those severe defects of patterning of the
great vessels and formation of the outflow tract are
not found to this extent in other KO models of the
endothelin system [45].
The surviving mice have craniofacial abnormalities
strikingly similar to those of the ET-1 KO and ETAR
KO animals. The animals also present with an absence
of epidermal melanocytes and enteric neurons of the
distal gut, the phenotype known from the ET-3 KO
and ETBR KO mice [18, 22]. This combined pheno-
type corroborates the assumption that ECE-1 by acti-
vating both ET-1 and ET-3 in vivo has an influence on
the development of distinct subsets of neural crest
cell lineages.
The tissue levels of ET-1, ET-2 and ET-3 were
measured as whole embryo extracts and compared to
those of WT animals. ET-3 is markedly reduced
whereas the levels of ET-1 and ET-2 are still about
50% of the WT mice. However, biologically active ET
seems not to be sufficiently produced at the sites cru-
cial for normal embryonic development.
Unlike the ECE-1 KO mice, animals with a ho-
mozygous KO of ECE-2 show no embryonic deve-
lopmental disorders. They are healthy, fertile and have
a normal life span [46].
A cross breeding of the two knockout lines brought
out animals with a lack of both ECE genes [46]. These
ECE1 -/-; ECE2 -/- animals show a similar but more
profound embryonic ECE-1 KO phenotype with the
same amount of ET-1 and ET-2 as in the ECE-1 KO
suggesting yet another protease to be also responsible
for the activation of ETs.
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Taken together, results from the different transgenic
and knockout models disclose that the ET system
plays a major role in embryonic development. Two ET
system-dependent neural crest-driven developmental
pathways become obvious: one of them being an
ET-1/ETAR axis, responsible for normal cardiac and
cranial development [47]; the other seems to be a
ET-3/ETBR mediated signalling pathway. Mutations
within this axis are associated with disruptions in epi-
dermal melanocytes and enteric neurons. These find-
ings led to the discovery of similar findings in humans
with Hirschsprung disease [48, 49].
In adult life the ET system is most important in the
renal and cardiovascular system as shown by a chroni-
cally activated ET system which results in a blood pres-
sure-independent fibrosis of kidneys and lungs. Espe-
cially collecting duct-derived ET-1 seems to have influ-
ence on the physiologic regulation of renal salt and wa-
ter handling and systemic blood pressure via ETBR.
The creation and investigation of genetically modi-
fied animals has contributed significantly to the under-
standing of ET function in vivo.
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